Karpov R S, Pavliukova E N, Kapishchenko T D, Chernov V I
Ter Arkh. 1995;67(9):50-3.
22 patients (mean age 45.08 +/- 1.38 years) with essential hypertension stage II were entered in a placebo-controlled blind trial of cilazapril, angiotensin-converting enzyme. A complex of clinical-instrumental tests comprised dipidamol test, bicycle ergometry, 199Tl myocardial scintigraphy, echo-CG. A 3-month course of cilazapril reduced myocardial hypoperfusion in 15 patients, improved left ventricular relaxation: Anti-ischemia effect of the drug was also evident.
22例II期原发性高血压患者（平均年龄45.08±1.38岁）进入了西拉普利（一种血管紧张素转换酶抑制剂）的安慰剂对照双盲试验。一组临床仪器检查包括双嘧达莫试验、踏车运动试验、199Tl心肌闪烁显像、超声心动图。为期3个月的西拉普利疗程使15例患者的心肌灌注不足得到改善，左心室舒张功能得到改善：该药物的抗缺血作用也很明显。
